TVRD
Tvardi Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.86
−2.73%Sep 24, 2026, 12:00 UTC
Tvardi Therapeutics announced the publication of preclinical data in the International Journal of Molecular Sciences supporting its STAT3 inhibitors, including TTI-109, for ulcerative colitis.
Source:Aug 14, 2026, 00:00 UTC
Tvardi Therapeutics reported a net loss of $6.5 million for Q2 2026, compared with net income of $4.2 million in Q2 2025, with research and development expenses of $4.0 million and general and administrative expenses of $2.6 million.